Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,724 recalls · Class II, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 20262025202420232022 All years
Cause Sterility / contaminationNitrosamine impurityChemical / undeclaredParticulate / foreign matterLabeling / mix-upcGMP deviationMicrobial contamination All causes
Class II · Moderate risk

Clarithromycin Tablets

cGMP Deviations; products being recalled in response to a recall notice from the manufacturer, Wockhardt Limited, following a FDA inspection which noted inadequate investigation of market complaints, resulting in unsuccessful identification of root causes, and the investigation not being expanded to prevent repeat failure

Terminated cGMP deviation Blenheim Pharmacal, Inc. NDC 10544-522-20 D-1110-2015
Class II · Moderate risk

Captopril Tablets

cGMP Deviations; products being recalled in response to a recall notice from the manufacturer, Wockhardt Limited, following a FDA inspection which noted inadequate investigation of market complaints, resulting in unsuccessful identification of root causes, and the investigation not being expanded to prevent repeat failure

Terminated cGMP deviation Blenheim Pharmacal, Inc. NDC 10544-175-30 D-1109-2015
Class II · Moderate risk

Famotidine Tablets

CGMP Deviations: Failure of the manufacturer, Wockhardt Ltd, to adequately investigate customer complaints.

Terminated cGMP deviation Allegiant Health D-1134-2015
Class II · Moderate risk

Azithromycin 500 mg tablets

cGMP Deviations: This recall is a result of the original manufacturer's recall, in which the firm did not adequately investigate customer complaints.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. D-0561-2016
Class II · Moderate risk

Azithromycin Tablets

cGMP Deviations: This recall is a result of the original manufacturer's recall, in which the firm did not adequately investigate customer complaints.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. D-0560-2016
Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1277-2015
Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1276-2015
Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1275-2015
Class II · Moderate risk

Zonisamide Capsules

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1274-2015
Class II · Moderate risk

Zonisamide Capsules

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1273-2015
Class II · Moderate risk

Famotodine Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1267-2015
Class II · Moderate risk

Famotodine Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1266-2015
Class II · Moderate risk

Famotodine Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1265-2015
Class II · Moderate risk

Azithromycin Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1264-2015
Class II · Moderate risk

Azithromycin Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1263-2015
Class II · Moderate risk

Zolpidem Tartrate Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1262-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1261-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1260-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1259-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1258-2015

Recalls by year